Most recently Bob served as President and Chief Executive Officer of DUSA Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical and medical device company focused in the field of dermatology.

I find the technology both fascinating and compelling as it could enable the company to avoid the obstacles that other RNA technologies like RNAi, antisense and microRNA have as of yet been unable to overcome.